TEMAZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Temaz, and what generic alternatives are available?
Temaz is a drug marketed by Quantum Pharmics, Actavis Elizabeth, Alembic, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Usa, Chartwell Rx, Duramed Pharms Barr, Novel Labs Inc, Prinston Inc, Sun Pharm Industries, Usl Pharma, and Watson Labs. and is included in twenty-three NDAs.
The generic ingredient in TEMAZ is temazepam. There are seven drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the temazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Temaz
A generic version of TEMAZ was approved as temazepam by NOVEL LABS INC on April 21st, 1987.
Summary for TEMAZ
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 23 |
Raw Ingredient (Bulk) Api Vendors: | 34 |
Patent Applications: | 4,113 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TEMAZ |
Drug Sales Revenues: | Drug sales revenues for TEMAZ |
DailyMed Link: | TEMAZ at DailyMed |